Evidence map›Paper›PMID 38072381›Full record

ArticleJournal of substance use and addiction treatment2024

Clinical stakeholders' perceptions of patient engagement in outpatient medication treatment for opioid use disorder: A qualitative study.

Melissa N Poulsen, Sophie A Roe, Patrick B Asdell, Alanna Kulchak Rahm, Wade Berrettini

Open access · greenAbstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Melissa N PoulsenDepartment of Population Health Sciences, Geisinger, Danville, PA 17822, USA. Electronic address: mpoulsen@geisinger.edu.
Sophie A RoeGeisinger Commonwealth School of Medicine, Scranton, PA 18509, USA. Electronic address: sroe@som.geisinger.edu.
Patrick B AsdellDepartment of Family Medicine, Summa Health, Barberton, OH 44203, USA. Electronic address: asdellp@summahealth.org.
Alanna Kulchak RahmDepartment of Genomic Health, Geisinger, Danville, PA 17822, USA. Electronic address: akrahm@geisinger.edu.
Wade BerrettiniDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. Electronic address: wadeb@pennmedicine.upenn.edu.
Geisinger Health System · USCommonwealth Medical College · USSumma Barberton Hospital · USUniversity of Pennsylvania · US

Funding

Understanding the role of community determinants in opioid use disorder and program implementation factors influencing patient adherence to opioid agonist therapyK01DA049903 · NIDA · GEISINGER CLINIC · PI POULSEN, MELISSA · 2020 to 2024
$810k
NIDA NIH HHS K01 DA049903
6 · The paper itself

Abstract

introductionMedications for opioid use disorder (MOUD) reduce risk of opioid overdose and promote recovery from opioid use disorder, but poor retention in MOUD limits these positive effects. This study explored patient engagement in MOUD from the perspective of clinical stakeholders within an outpatient addiction medicine program to identify program factors influencing patient engagement with treatment.

methodsWe conducted a qualitative case study of a multi-clinic outpatient addiction medicine program embedded within an integrated health system that serves a geographically diverse area of Pennsylvania. Collectively, the program's clinics provide MOUD (primarily buprenorphine) to ~2000 patients annually. From January to March 2021, we conducted semi-structured telephone/video interviews with three stakeholder groups involved in delivering MOUD: administrators (n = 4), providers (n = 7), and addiction care coordinators (n = 5). Data analysis utilized the framework method.

resultsWe identified five themes related to patient engagement. First, participants described health system integration as enhancing quality and offering opportunities for addressing patients' comprehensive health care needs. However, lack of knowledge about addiction and stigma among health system providers was felt to limit patient benefits from this integration, including access to MOUD. Second, participants viewed patient engagement as central to the program's policies, practices, and clinical environment. Adoption of a harm reduction approach and maintenance of a non-stigmatizing clinic environment were described as essential facilitators of engagement. Third, while clinics followed uniform operations, physician leads expressed differing philosophical approaches to treatment, which participants associated with variations in clinical practice and patient engagement. Fourth, participants identified key services that bolstered engagement in MOUD, including psychosocial services, psychiatric care, and telemedicine. Finally, staff well-being emerged as a key consideration for patient engagement.

conclusionsUnderstanding perceptions of those who administer and deliver care is critical for identifying barriers and facilitators to patient engagement in MOUD. Findings suggest potential opportunities for addiction treatment programs to improve patient engagement and ultimately MOUD retention, including integration with other healthcare services to meet comprehensive healthcare needs; adoption of a harm reduction approach; creation of non-stigmatizing clinical environments; investment in psychosocial services, psychiatric care, and telemedicine; and prioritization of staff wellness.

Indexed as

Opioid-Related DisordersOutpatientsAmbulatory CareAmbulatory Care FacilitiesHumansPatient ParticipationBuprenorphineImplementationOpioid-related disordersOpioid treatment programQualitative research

Identifiers

PMID38072381
PMCPMC10947908
OpenAlexW4389513888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.